The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The submission is backed by positive results from the Phase 3 AFFIRM study
The approval was driven by data from the Phase III TULIP-SC trial
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
nSEPIA aims to bring structure to an area long dominated by subjectivity
Subscribe To Our Newsletter & Stay Updated
